Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Germany's Bundestag extends two armed forces missions abroad - 2Cuba fights to contain spread of mosquito-borne chikungunya virus
- 3Famous Versatile Brands: Your Decision
- 4Reclassifying Achievement: Individual Accounts of Seeking after Interests
- 5An Extended time of Self-Reflection: Self-awareness through Journaling
- Israeli Chief of Staff declares new border with Gaza Strip
- Get away from the Tedious Drudgery: Go into Business Today!
- Shooting of MIT professor Nuno Loureiro has police searching for a suspect
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Moon milestones: A rundown of Artemis 2's many spaceflight firsts
- Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts
- Massive supernova explosion may have created a binary black hole
